Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data
Globe Newswire•13/11/2026•07:08 ET
0
Key Highlights
- ➤CARDAMYST Q3 product revenue reached $1.0 million, up 73% sequentially
- ➤Operating expenses targeted for approximately 30% reduction by Q1 2027
- ➤Cash runway extended into late 2028 with $145.4 million available
- ➤ReVeRA-301 Phase 3 AFib-RVR topline data expected in second half of 2028
- ➤Approximately 3,400 prescriptions written by 1,600 prescribers since launch
Expert Statements
Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals
“We are encouraged by the early progress of CARDAMYST, and as we gain experience in the market, we believe we are better able to identify where our investments can have the greatest potential impact”
Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals
“The actions we are announcing today reflect a more efficient approach to capital allocation, which we believe will drive continued prescription growth, expand our prescriber base and improve patient access for CARDAMYST, while reducing operating expenses.”
Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals
“Importantly, we expect these measures to extend our cash runway beyond the anticipated Phase 3 readout of ReVeRA-301 in the second half of 2028.”
Launch of CARDAMYST(®) (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage
Company is reducing operating expenses by approximately 30% while prioritizing sales force efforts for CARDAMYST; expects cash runway into late 2028
Get started
Create a free account to read the full story.